NS-2710

From Wikipedia, the free encyclopedia
Jump to: navigation, search
NS-2710
NS-2710.png
Systematic (IUPAC) name
1-[1-[3-(3-pyridyl)phenyl]benzimidazol-5-yl]ethanone O-ethyloxime
Clinical data
Legal status
?
Identifiers
ATC code ?
PubChem CID 21310187
Chemical data
Formula C22H20N4O 
Mol. mass 356.420 g/mol
 YesY (what is this?)  (verify)

NS-2710 (LS-193,970) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company Neurosearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2710 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has anxiolytic effects comparable to chlordiazepoxide,[1] and while it is a less potent anticonvulsant than the related drug NS-2664, it has a much longer duration of action, and similarly to other α2/α3-preferring partial agonists produces little sedative effects or physical dependence.[2]

References[edit]

  1. ^ Evenden J, Duncan B, Ko T. A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat. Behavioural Pharmacology. 2006 Feb;17(1):87-99. PMID 16377966
  2. ^ Mirza NR, Nielsen EØ. Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? Journal of Pharmacology and Experimental Therapeutics. 2006 Mar;316(3):1378-85. PMID 16352707